Adam R. Craig
2018
In 2018, Adam R. Craig earned a total compensation of $3M as President, Chief Executive Officer and Interim Chief Medical Officer at CTI BioPharma, a 46% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $311,575 |
---|---|
Option Awards | $2,149,080 |
Salary | $563,750 |
Other | $8,250 |
Total | $3,032,655 |
Craig received $2.1M in option awards, accounting for 71% of the total pay in 2018.
Craig also received $311.6K in non-equity incentive plan, $563.8K in salary and $8.3K in other compensation.
Rankings
In 2018, Adam R. Craig's compensation ranked 3,823rd out of 14,244 executives tracked by ExecPay. In other words, Craig earned more than 73.2% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,823 out of 14,244 | 73rd |
Division Manufacturing | 1,412 out of 5,765 | 76th |
Major group Chemicals And Allied Products | 502 out of 2,128 | 76th |
Industry group Drugs | 419 out of 1,817 | 77th |
Industry Pharmaceutical Preparations | 326 out of 1,391 | 77th |
Source: SEC filing on April 4, 2019.
Craig's colleagues
We found three more compensation records of executives who worked with Adam R. Craig at CTI BioPharma in 2018.